Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03965468). This is a study registration, not published results. Lead sponsor: ETOP IBCSG Partners Foundation. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 96 participants (ESTIMATED). Conditions: Non-small Cell Lung Cancer, Stage IV, Oligometastasis. Interventions: DRUG: Durvalumab; DRUG: Carboplatin; DRUG: Paclitaxel; RADIATION: Stereotactic body radiation therapy (SBRT); PROCEDURE: Surgical resection - definitive local treatment.; RADIATION: Radical radiotherapy - definitive local treatment.; DRUG: Tremelimumab. Primary outcome measures: Progression-free survival at 12 months , Assessed from the date of enrolment to completion of treatment at 12 months.. Brief summary: A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in patients with histologically-confirmed synchronous oligo-metastatic non-small cell lung cancer (NSCLC).